AmpliMed pockets $5M in second round

AmpliMed has raised $5 million in its second round of venture capital. The oncology drug developer plans to use the money to push its products in clinical development.

"This is an exciting time for the company as our Amplimexon clinical development program is expanding rapidly and we plan to bring additional new drugs into clinical trials in the near future," said Robert A. Ashley, Chairman, president and CEO of AmpliMed. "This funding will help us to continue these efforts as well as research additional late-stage clinical development opportunities."

- read this release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.